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Abstract 
The turn of the 21st century had witnessed a surge of interest in the centrosome and its causal 
relation to human cancer development - a postulate that has existed for almost a century. 
Centrosome amplification (CA) is frequently detected in a growing list of human cancers, both 
solid and haematological, and is a candidate "hallmark" of cancer cells. Several lines of evidence 
support the progressive involvement of CA in the transition from early to advanced stages of 
carcinogenesis,  being also  found  in  pre-neoplastic  lesions and  even  in histopathological-
ly-normal tissue. CA constitutes the major mechanism leading to chromosomal instability and 
aneuploidy, via the formation of multipolar spindles and chromosomal missegregation. Clin-
ically, CA may translate to a greater risk for initiation of malignant transformation, tumour 
progression, chemoresistance and ultimately, poor patient prognosis. As mechanisms un-
derlying CA are progressively being unravelled, the centrosome has emerged as a novel 
candidate target for cancer treatment. This Review summarizes mainly the clinical studies 
performed to date focusing on the mechanisms underlying CA in human neoplasia, and 
highlights the potential utility of centrosomes in the diagnosis, prognosis and treatment of 
human cancers. 
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Introduction 
Genomic instability is a hallmark of cancer cells, 
and may be broadly classified based on origin into 
chromosomal instability (CIN) and the less common 
microsatellite  instability  (MIN).  CIN,  describing  the 
accelerated  rate  of  change  in  chromosome  number, 
gives rise to states of aneuploidy [1]. The mechanisms 
underlying  CIN  remain  largely  unknown,  but  may 
include  defects  in  chromosome  cohesion,  mitotic 
checkpoint  function,  centrosome  copy  number,  ki-
netochore-microtubule  attachment  dynamics,  and 
cell-cycle regulation [2]. A causal association between 
centrosome  amplification  (CA)  and  human  cancer 
development has long been hypothesized [3], yet ev-
idence  for  this  proposal  has  not  been  firmly  estab-
lished. CA is detected in a broad range of tumours, 
both solid and haematological, and is implicated as 
the  major  mechanism  underlying  the  generation  of 
multipolar  mitoses,  CIN,  and  aneuploidy.  Several 
oncogenic and tumour suppressor proteins are known 
to localize to the centrosomes, deregulation of which 
may  evoke  centrosome  abnormalities  [4].  Emerging 
data are demonstrating the detection of centrosome 
defects in several pre-neoplasia, as well as the corre-
lation of more extensive centrosome alterations in the 
continuum  of  advancing  disease.  Intuitively,  this 
supports a non-bystander role in both tumourigenesis 
and disease progression. Moreover, the frequent as-
sociation  with  extensive  karyotypic  aberrations  and 
poor patient outcome supports its clinical significance 
in human cancer [Tables 1-3]. 
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Table 1. Centrosome amplification in human solid tumours. 
Cancer site  n  CA (%)  CIN  Association  Ref 
Samples  Intratumoural 
Breast             
NOS  19  95  -  -  -  [10] 
NOS   19  95  10  -  Nuclear AhR expression   [65] 
AC  30  -  -  -  Cytoplasmic LMW Cyclin E  [41] 
AC  35  97  -  -  -  [25] 
AC  31  77  -  -  -  [26]  
IDC  8  75  -  -  -  [153] 
IDC  20  100  -  Y  p53 mutation  [27] 
AC  103  89  46  -  HER2 positive 
ER/PR negative  
˟p53, BCL2 
[34] 
AC  56  100  -  N  Pin1 expression  [61] 
AC  75  100  7    HER2 positive 
ER/PR negative 
[35] 
AC  50  100  1-87  N  BRCA1 mutation 
˟Aurora-A, p53, ER/PR, HER2 
[37] 
AC - Diploid 
 - Aneuploid 
3 
13 
100 
100 
-  Y  ˟p53, ER  [33] 
AC - Diploid 
 - Aneuploid-stable 
 - Aneuploid-unstable 
3 
3 
4 
100 
100 
100 
3 
2 
10 
Y  Cyclin E/A expression  [32] 
AC - Diploid 
 - Aneuploid-stable 
 - Aneuploid-unstable 
12 
7 
14 
100 
100 
100 
2 
2 
10 
Y  -  [29] 
DCIS + IDC  21  100  30-100  Y  Aurora-A expression  [52] 
DCIS  7  Most  -  -  -  [27] 
DCIS  42  75  -  Y  -  [28] 
DCIS  7  100  8  Y  -  [29] 
Ovarian             
Mainly endometroid and serous  63  78  -  -  -  [102] 
Mainly serous  18  100  -  -  Aurora-A expression  [105] 
NOS  10  100  17  Y  -  [103] 
Anogenital             
AC  5  100  8  Y  High-risk HPV  [84] 
CIN*  14  71  2  Y  High-risk HPV  [84] 
CIN*  48  62  -  Y  -  [28] 
Anal SCC 
Anal LSIL 
Anal HSIL 
14 
13 
6 
100 
100 
100 
5.8 
2.5 
4.7 
-  High-risk HPV  [205] 
Prostate             
AC  18  89  -  -  -  [10] 
AC  140  94  15-100  Y  -  [66] 
AC  63  -  -  Y  -  [67] 
PIN  45  28  -  Y  -  [28] 
Testicular             
Infantile yolk sac tumour 
Infantile teratoma 
Seminoma 
Mixed non-seminoma 
Embryonal carcinoma 
Teratoma 
Spermatocytic seminoma 
1 
6 
11 
12 
2 
1 
3 
100 
33 
100 
100 
100 
100 
100 
- 
20 
- 
- 
- 
- 
60 
Y  ˟Aurora-A expression  [104] 
Urothelial             
Bladder TCC  22  82  -  Y  -  [71] 
Bladder TCC  45  89  9-100  Y  -  [70] 
Bladder TCC  50  60  -  Y  20q gain  [72] 
Bladder TCC  65  52  -  -  Cyclin E expression 
p53 mutation 
[76] 
Renal + Ureteral TCC  90  50  -  Y  20q gain  [74] 
Bladder TCC  100  64  -  Y  20q gain 
Aurora-A expression 
[73] 
Bladder TCC  101  101  65  -  PLK1/Aurora-A expression 
p53 mutation 
[79] 
Bladder TCC  104  65  -  -  BUBR1 expression  [80] 
Bladder TCC  21  60  -  Y  Cyclin D1 amplification  [75] 
Renal             
RCC  8  25  10  Y  Telomere dysfunction  [81] Int. J. Biol. Sci. 2011, 7 
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Cancer site  n  CA (%)  CIN  Association  Ref 
Samples  Intratumoural 
Adrenal             
Carcinoma 
Adenoma 
10 
4 
100 
100 
1-7 
1-19 
-  -  [83] 
Neural             
NOS  20  95  -  -  -  [10] 
Cerebral PNET  2  100  -  Y  p53 mutation  [140] 
Pituitary adenoma  12  100  -  Y  Securin expression  [142] 
Diffuse astrocytic glioma  46  100  -    -  [141] 
Glioma  34  -  -  -  Aurora-A mRNA expression  [144] 
Neuroblastoma  20  -  -  -  MYCN amplification  [153] 
Neuroblastoma  27  89  23  Y  ˟MYCN  [149] 
Medulloblastoma  20  -  -  -  -  [143] 
Lung             
NOS  15  100  -  -  -  [10] 
AC 
SCC 
19 
40 
53 
58 
-  Y  Cyclin E/E2F1 expression 
˟p53 
[128] 
AC 
SCC 
88 
87 
33 
24 
-  Y  p16 expression 
pRb loss 
˟p53 
[129] 
Colorectal             
AC  15  87  -  -  -  [10] 
AC  33  -  -  -  -  [108] 
AC 
Adenoma 
30 
54 
100 
65 
-  -  TEIF expression  [109] 
Pancreatic             
Ductal 
Endocrine 
13 
3 
85 
0 
-  -  -  [122] 
Adenoma  3  67  -  -  -  [122] 
Hepatobiliary             
GC 
CCC 
BDC 
Chronic cholecystitis 
Adenomatous polyp 
Hepatolithiasis 
Choledochal cyst 
13 
19 
8 
15 
1 
16 
5 
69 
58 
50 
7 
0 
6 
0 
-  -  -  [116] 
HCC  33  91  8.9  Y  p53 mutation  [117] 
Head & Neck             
Thymic carcinoid tumour  1  100  -  -  -  [160] 
SCC  12  83  -  -  p53 mutation 
MDM2 expression 
[153] 
Oral SCC  18  94  -  -  -  [154] 
SCC 
PA 
5 
3 
100 
100 
-  Y  Telomere dysfunction  [155] 
SCC  29  62  -  -  Aurora-A expression  [156] 
Oral SCC 
Dysplasia 
15 
25 
100 
100 
<1-5 
<1-4 
-  -  [158] 
SCC  50  -  41  Y  -  [157] 
Laryngeal SCC  35  94  -  -  -  [159] 
BSTT             
Leiomyosarcoma  1  100  -  -  -  [162] 
Osteosarcoma  3  67  25  -  -  [163] 
Liposarcoma 
Chondrosarcoma 
MFH 
Haemangiopericytoma 
Atypical lipomatous tumour 
Giant cell tumour 
Benign or tumour-like lesions† 
7 
5 
5 
1 
2 
1 
7 
87 
60 
100 
100 
50 
100 
29 
-  Y  -  [164] 
Liposarcoma 
 - Type D near-diploid 
 - Type H near-tetraploid 
Lipoma 
 
3 
3 
9 
 
100 
100 
Rare 
 
29-50 
53-71 
- 
N  -  [165] 
Peripheral PNET 
Synovial sarcoma 
Rhabdomyosarcoma 
MFH 
MPNST 
Liposarcomma 
Leiomyosarcoma 
Benign or tumour-like lesions‡ 
9 
8 
9 
35 
18 
14 
11 
14 
89 
75 
67 
63 
39 
21 
18 
29 
>15%  -  TEIF expression  [166] 
Giant cell tumour        N  -  [167] Int. J. Biol. Sci. 2011, 7 
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Cancer site  n  CA (%)  CIN  Association  Ref 
Samples  Intratumoural 
 - Nonrecurrent 
 - Recurrent 
 - Malignant 
57 
35 
8 
66 
95 
100 
5 
17 
37 
n, sample size; CA, centrosome amplification; CIN, chromosomal instability/aneuploidy; AC, adenocarcinoma; IDC, invasive ductal carci-
noma; DCIS, ductal carcinoma in-situ; CIN*, cervical intraepithelial neoplasia; LSIL, low-grade squamous intraepithelial lesion; HSIL, 
high-grade squamous intraepithelial lesion; PIN, prostate intraepithelial neoplasia; TCC, transitional cell carcinoma; PNET; primitive neu-
roectodermal tumour; SCC, squamous cell carcinoma; GC, gallbladder cancer; CCC, cholangiocellular carcinoma; BDC, bile duct cancer; 
HCC, hepatocellular carcinoma; PA, pleomorphic adenoma; BSTT, bone and soft tissue tumours; MFH, malignant fibrous histiocytoma; 
MPNST, malignant peripheral nerve sheath tumour; NOS, not otherwise specified; ˟, no association. 
†Includes melorheostosis, lipoma, myxoma, granular cell tumour, non-ossifying fibroma, schwannoma, pigmented villonodular synovitis. 
‡Includes leiomyoma, neurilemoma, lipoma, and fibrous histiocytoma. 
 
Table 2. Centrosome amplification in human haematological cancers and pre-neoplasia 
Cancer type  n  CA (%)  CIN  Association  Ref 
Samples  Intratumoural 
cHL  2  100  -  -  ˟Aurora-A, PLK1  [177] 
cHL  31  90  -  -  -  [178] 
Total NHL 
DLBCL 
MCL 
 - Tetraploid 
 - Diploid 
FL 
 - High grade 
 - Low grade 
MZBCL 
92 
18 
 
12 
19 
 
8 
16 
17 
100 
100 
 
100 
100 
 
100 
100 
100 
32 
42 
 
56 
31 
 
30 
23 
29 
- 
- 
Y 
 
 
- 
 
 
- 
˟p53  [175] 
MCL 
 - Tetraploid 
 - Diploid 
 
9 
24 
 
100 
100 
 
56 
36 
Y  -  [179] 
BL  1  100  30-50  N  -  [182] 
B-CLL  64  100  18  N  -  [180] 
B-CLL 
MBL 
70 
4 
100 
100 
26 
12 
N  -  [176] 
ALCL  17  41  -  -  ˟p53  [181] 
CML 
 - CP 
 - BC 
 
18 
16 
 
100 
100 
 
29 
54 
Y  -  [183] 
CML 
 - CP 
 - BC 
 
5 
5 
 
100 
 
35 
59 
-  -  [184] 
CML (CP) 
SM 
29 
2 
100 
100 
13-26 
16 
-  -  [188] 
AML  51  100  36  Y  -  [190] 
Marrow failure 
 - AA 
 - MDS 
 - PNH 
 
15 
9 
1 
 
27 
11 
0 
10-24  Y  -  [192] 
ATL  8  88  19  -  -  [194] 
MM (Plasma cells) 
MGUS 
41 
8 
100 
- 
26 
14 
-  RHAMM expression  [197] 
MM (Plasma cells) 
SMM 
MGUS 
14 
7 
3 
64 
71 
67 
26 
20 
12 
N  -  [12] 
MM 
 - Plasma cells 
 - B cells 
 
50 
38 
 
17 
37 
 
9 
10 
-  -  [198] 
GIST  1  100  17  -  -  [188] 
n, sample size; CA, centrosome amplification; CIN, chromosomal instability/aneuploidy; cHL, classic Hodgkin's lymphoma; NHL, 
non-Hodgkin's lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; FL, follicular lymphoma; MZBCL, mar-
ginal zone B-cell lymphoma; BL, Burkitt's lymphoma; B-CLL, B-cell chronic lymphocytic leukaemia; MBL, monoclonal B-cell lymphocytosis; 
ALCL, ALK-positive anaplastic large cell lymphoma; ATL, adult T-cell leukaemia; AML, acute myeloid leukaemia; CML, chronic myeloid 
leukaemia; CP, chronic phase; BC, blast crisis; SM, systemic mastocytosis; AA, aplastic anemia; MDS, myelodysplastic syndrome; PNH, 
paroxysmal nocturnal hemoglobinuria; MM, multiple myeloma; SMM, smouldering multiple myeloma; MGUS, monoclonal gammopathy of 
undetermined significance; ˟, no association; Y, positive association; N, no association 
 Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
1126 
Table 3. Clinical correlates of centrosome aberration in human tumours 
Cancer type 
 
Patient cohort  Correlation  Ref 
Breast  AC, surgical resection, n = 16  Nodal metastasis  [33] 
  IDC, surgically treated, n = 20  Tumour grade  [27] 
  DCIS, surgically treated, n = 42  Tumour grade  [28] 
  AC, surgically treated 
(6 received neoadjuvant chemotherapy), n = 103 
Axillary nodal metastasis 
Not with tumour size, nuclear grade, DNA index, 
S-phase fraction, or proliferation index 
[34] 
  Mainly IDC, surgically treated, n = 10  Tumour grade  [32] 
  AC, surgically treated, n = 73  Not with tumour size, grade, or nodal metastasis  [35] 
  Mainly IDC, surgically treated, n = 50  Not with tumour size, tumour grade, or nodal me-
tastasis 
[37] 
  NOS, surgically treated, n = 30  Tumour grade  [41] 
Prostate  AC, surgically treated, n = 140  Tumour grade and distant metastasis  [66] 
  AC, surgically treated, n = 63  Tumour grade and stage  [67] 
  PIN, surgically treated, n = 45  Tumour grade  [28] 
Bladder  TCC, surgically treated, n = 45 
TCC, surgically treated, n = 22 
TCC, surgically treated, n = 65 
Tumour grade  [70] 
[71]  
[76] 
  TCC, surgically treated, n = 50  Tumour number, grade, poor recurrence-free sur-
vival, and PFS 
[72] 
  TCC, surgically treated, n = 100  Disease progression  [73] 
Renal/ Ureteral  TCC, surgically treated, n = 90  Tumour grade 
Not with intravesical or local recurrence, distant 
metastasis, or cancer-specific death 
[74] 
Cervix  CIN, surgically treated, n = 14  Tumour grade  [84] 
  CIN, surgically treated, n = 48  Tumour grade  [28] 
Ovary  Mainly endometroid and serous 
Surgically treated, n = 63 
Stage, tumour grade  [102] 
Colorectum  AC, surgically treated, n = 30 
Adenoma, surgically treated, n = 54 
Tumour grade of CRC and adenoma  [109] 
Hepatobiliary  GC + CCC + BDC, surgically treated, n = 40  Stage  [116] 
  HCC, surgically treated, n = 33  Not with tumour size, stage, or proliferative activity  [117] 
Lung  AC + SCC, surgically treated, n = 59  Not with stage, tumour grade  [128] 
  AC + SCC, surgically treated, n = 175  Not with tumour type, age, gender, size, stage, or 
cancer-specific death 
[129] 
Neural  Diffuse astrocytic glioma, surgically treated, n = 46  Tumour grade  [141] 
  Glioma, surgically treated, n=34  Tumour grade  [144] 
Head & neck  Oral SCC, surgically treated +/- RT, n = 18  Tumour recurrence  [154] 
  Oral SCC, surgically treated, n = 15  Tumour grade  [158] 
  SCC, surgically treated, n = 50  Tumour size, stage, distant metastasis, poor DFS, and 
OS 
[157] 
  Laryngeal SCC, surgically treated, n = 35  Tumour recurrence  [159] 
BSTT  Soft tissue sarcoma, surgically treated, n = 104  Tumour grade  [166] 
  Giant cell tumour, surgically treated, n = 100  Tumour recurrence and malignancy  [167] 
Blood  NHL, n = 92  Tumour grade (FL), mitotic and proliferation indices 
(FL, DLBCL, MCL) 
[175] 
  CML (chronic phase), n = 34  Not with Hasford score  [183] 
  AML, n = 51  Cytogenetically-defined risk groups  [190] 
  B-CLL, untreated, n = 70  Lymphocyte doubling time, time to 1st treatment 
Not with IgVH genes mutation status or cytogenet-
ically-defined risk groups 
[176] 
  MM, multiple modalities†, n = 97  High CI with Chr 13 deletion, t(4;14), t(14;16), high 
plasma cell labelling index, and poor OS 
[12] 
  MM, multiple modalities‡, n = 539  High CI with poor PFS and OS  [199] 
n, sample size; AC, adenocarcinoma; IDC, invasive ductal carcinoma; PIN, prostate intraepithelial neoplasia; HCC, hepatocellular carcino-
ma; GC, gallbladder cancer; CCC, cholangiocellular carcinoma; BDC, bile duct cancer; SCC, squamous cell carcinoma; TCC, transitional cell 
carcinoma; CIN, cervical intraepithelial neoplasia; NHL, non-Hodgkin's lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B-cell 
lymphoma; MCL, mantle cell lymphoma; CML, chronic myeloid leukaemia; B-CLL, B-cell chronic lymphocytic leukaemia; AML, acute 
myeloid leukaemia; MM, multiple myeloma; CI, centrosome index; PFS, progression-free survival; DFS, disease-free survival; OS, overall 
survival. 
†Includes single autologous stem cell transplantation, dexamethasone-based, melphalan and prednisolone, novel agents, thalidomide-based 
‡Includes chemotherapy, high-dose therapy with stem cell transplantation, total therapy II, and novel agents such as bortezomib 
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 The centrosome constitutes the major microtu-
bule organizing centre of the cell (MTOC) in mamma-
lian cells, and plays a dominant role in the mainte-
nance  of  cell  polarity  and  cytoplasmic  architecture 
through  the  nucleation  and  spatial  organization  of 
microtubules [5], as well as in coordinating efficient 
cell cycle progression [6]. Structurally, the centrosome 
is  a  tiny  cytoplasmic  organelle  consisting  of  a  core 
formed by a pair of orthogonally-arranged centrioles, 
embedded in a structurally complex amorphous pro-
tein matrix termed the pericentriolar material (PCM). 
Centrioles  are  small  barrel-shaped  organelles  con-
sisting of a cylindrical array of nine triplet microtu-
bules,  whilst  the  PCM  is  composed  of  a  lattice  of 
coiled-coil  proteins  including  gamma-tubulin  ring 
complexes,  pericentrin  [7],  and  calcium-sensitive  fi-
bres such as Sfi1p and centrin [8]. During a normal 
cell cycle, centrosome duplication occurs strictly once 
to yield two centrosomes that function as the spindle 
poles of the dividing cell [9]. The centrosome dupli-
cation  cycle  is  exactly  coordinated  with  cell  cycle 
progression, and is tightly coupled to DNA replica-
tion, mitosis, and cytokinesis through parallel path-
ways of regulation. The presence of only two centro-
somes in the cell as it enters mitosis favours the for-
mation of a bipolar spindle and the equipartition of 
chromosomes to each daughter cell. 
 Centrosome defects observed in human cancers 
may  be  classified  into  2  broad  categories  based  on 
structural or functional alterations. Structural defects 
include  changes  in  centrosome  shape  (string-like 
elongated linear arrays, ring-like, amorphous, atypi-
cal filaments, corkscrew), size (usually  large patchy 
aggregates, but may range from tiny flecks), number 
(more than 2 per cell), position (diffuse patchy cyto-
plasmic staining, scattered, clustered) and/or compo-
sition (higher protein levels, inappropriate phosphor-
ylation,  absent  centrioles).  Functionally,  defective 
centrosomes  are  capable  of  abnormal  microtubule 
nucleation,  and  formation  of  disorganized  mitotic 
spindles, leading to chromosomal missegregation and 
aneuploidy [10-12]. These defects, collective referred 
to as CA, are major contributors to mechanisms un-
derlying loss of cell cycle fidelity, genomic instability 
and loss of tissue architecture in human cancers. 
 CA can arise via several fundamentally distinct 
but yet not mutually exclusive mechanisms. Firstly, 
deregulation of the centrosome duplication cycle may 
occur,  leading  to  centriole  overduplication  (loss  of 
cell-cycle control) or excessive centriole multiplication 
(loss of copy number control) during a single S-phase. 
The  former  involves  successive  rounds  of  centriole 
reproduction, whilst the latter entails the rapid sim-
ultaneous formation of multiple daughter centrioles at 
single maternal centriole templates. Both would result 
in  the  formation  of  supernumerary  centrosomes  in 
near-diploid cells [13]. Secondly, failure of cytokinesis 
may  generate  polyploid  cells  with  supernumerary 
centrosomes  [14].  In  such  cells,  centrosome  number 
accumulates  in  parallel  with  nuclear  abnormalities 
and do not primarily originate from enhanced dupli-
cation. The potential for such cells to re-enter S-phase 
and give rise to viable progeny seems to depend at 
least  partially  on  the  fidelity  of  the  tetraploidy 
checkpoint governed by p53 function, which in such 
cells triggers cell cycle arrest and apoptosis. Thirdly, 
centrosome number can increase via cell fusion, for 
example, when cells are under the influence of fuso-
genic viruses [15, 16]. Fourthly, functional centrioles 
may also form de novo [17, 18]. Lastly, the disintegra-
tion of centrosomes via fragmentation of PCM may 
lead to an appearance of CA which otherwise may not 
necessarily  be  functional  [19,  20].  The  exact  mecha-
nisms triggering CA and the relative importance of 
each of their contribution towards the development of 
specific  human  cancers  remain  under  intensive  re-
search. The issue gets further complicated since the 
presence  of  extra  centrosomes  does  not  necessarily 
lead to major cell division errors as extra centrosomes 
have been demonstrated to undergo clustering [21], or 
even gradual inactivation [22] during mitosis, thereby 
preserving  bipolarity  of  the  mitotic  spindle.  At  the 
same time, a limited level of CIN that permits con-
tinued bipolar cell division may be maintained con-
sequent  to  segregation  errors  via  merotelic  kineto-
chore-microtubule  attachment  possibly  during  a 
transient  „multipolar  spindle  intermediate‟  prior  to 
centrosome  clustering  and  anaphase  [23].  Still,  cells 
with amplified centrosomes are often too unstable to 
survive,  and  are  eliminated  through  cell  death 
mechanisms such as apoptosis, mitotic catastrophe, or 
replicative senescence [23, 24]. It is likely in order for 
tumourigenesis  to  occur,  these  selection  forces  ulti-
mately must result in the generation of a rare centro-
some-amplified, genomically-unstable but yet viable 
cellular subclone. In possession of a sustainable mu-
tator phenotype, cells that eventually harbour the rare 
genomic complement that confer survival advantage 
through  a  Darwinian  selection  process  would  pro-
mote cancer development and progression [Figure 1]. 
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Figure 1. Model supporting centrosome amplification as a cause of carcinogenesis. Centrosome amplification 
has been detected in broad range of tumours, both solid and haematological, and has been implicated in the generation of 
multipolar mitoses, chromosomal instability (CIN), and aneuploidy. Centrosome amplification also contributes to loss of 
tissue architecture, and possibly angiogenesis in human cancers. Defective centrosomes are capable of abnormal micro-
tubule nucleation and formation of disorganized mitotic spindles, leading to chromosomal missegregation and aneuploidy. 
However, the presence of extra centrosomes does not necessarily lead to major cell division errors as extra centrosomes 
may undergo clustering, thereby preserving bipolarity of the mitotic spindle. Ultimately, the "mutator phenotype" generated 
as a result raises the possibility of producing cells with the rare genomic complement that may confer survival advantage 
through a Darwinian selection process, thereby promoting cancer development and progression. 
 
Despite the vastly expanding amount of studies 
demonstrating the clinical relevance of CA in human 
cancers, there is as yet no comprehensive review of 
the  existing  literature.  This  Review  will  summarize 
studies performed to date implicating CA on human 
neoplasia,  with  a  focus  on  those  based  on  human 
cancer tissue samples.  Relevant  in vitro studies that 
shed light on the underlying mechanisms leading to 
CA in specific tumour types are also included. Finally, 
the potential utility of centrosomes in the diagnosis, 
prognosis  and  treatment  of  human  cancers  are  dis-
cussed. 
Centrosome amplification in solid tumours 
Breast cancer 
 In primary human cancers, structural alterations 
of centrosomes have been first systematically studied 
in specimens of high grade metastatic breast adeno-
carcinoma. Several centrosome defects, including an 
increase  in  centrosome  number  and  volume,  with 
chaotic subcellular locations, accumulation of exces-
sive PCM, supernumerary centrioles, as well as inap-
propriate  accumulation  of  phosphocentrin  during 
non-mitotic phases are frequently observed. In addi-
tion,  breast  tumour  cells  display  functional  centro-
some  abnormalities,  as  characterized  by  unusually 
large  arrays  of  microtubules  nucleated  by  an  in-
creased number of MTOCs [25]. Ultrastructural anal-
ysis of centrosomes via electron microscopy revealed 
that breast tumour cells contain numerous large cen-
trioles  surrounded  by  abundant  densely-stained 
PCM, disrupted centriole barrel structure (open-ring 
and  missing  triplet  microtubules),  unincorporated 
microtubule complexes, centrioles of unusual length, 
centrioles  functioning  as  ciliary  basal  bodies,  and Int. J. Biol. Sci. 2011, 7 
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mispositioned  centrioles  [25,  26].  Interestingly,  tu-
mours  with  excess  PCM  are  highly  anaplastic,  lack 
normal cell polarity, and tend to have a higher median 
frequency of abnormal mitoses compared to tumours 
with other centrosome abnormalities [26]. 
 Supporting CA as a causal and early event  in 
breast  tumourigenesis,  CA  is  also  present  in  ductal 
carcinoma in-situ (DCIS), and correlates with CIN in 
these lesions [27-29]. Gamma-tubulin gene amplifica-
tion and the concomitant protein overexpression are 
also seen in atypical ductal hyperplasia of the breast, 
albeit significantly lower than in lesions of DCIS and 
invasive ductal carcinoma (IDC) [30, 31]. Moreover, 
within  DCIS  lesions,  centrosome  defects  increases 
with advanced histological grade, which  suggests a 
higher propensity of evolution into invasive carcino-
ma [28]. 
 Kronenwett  et  al.  classified  aneuploid  human 
breast cancers into genomically-stable and -unstable 
subtypes  using  a  surrogate  marker  based  upon  the 
proportion  of  cells  with  non-modal  DNA  content 
values referred to as the Stemline Scatter Index (SSI) 
[32]. In keeping with earlier studies [27], greater CA, 
along with aberrant mitotic spindles are observed in 
genomically-unstable and clinically more aggressive 
aneuploid breast cancers with high SSI, compared to 
genomically-stable  aneuploid  and  diploid  counter-
parts [29, 32]. Furthermore, CA correlates with high 
histological grade and lymph node metastasis in most 
studies, supporting it as a possible marker for aggres-
sive disease and poor prognosis in breast cancer [27, 
32-35].  The  implication  of  CA  upon  breast  cancer 
prognosis is further supported by its association with 
HER2/neu overexpression, negative estrogen recep-
tor  (ER)  status,  and  negative  progesterone  receptor 
(PR) status in some studies [34-36]. One study how-
ever, did not find any association of CA with CIN, nor 
with  hormonal  receptor  status,  HER2/neu  status, 
tumour size, grade or nodal status [37]. 
 Numerous  studies  have  been  performed  at-
tempting to uncover the underlying mechanisms and 
significance  of  CA  in  breast  cancer  development. 
Available evidence suggests a cooperative model of 
different  mechanisms  for  the  development  of  CA 
during breast carcinogenesis. In human breast carci-
noma, both centrosome size and number, but not mi-
crotubule nucleation capacity, shows a positive cor-
relation with aneuploidy and CIN that is independent 
of p53 mutation [27, 33, 37]. Centrosomal microtubule 
nucleation capacity is enhanced with  p53 mutation, 
and in addition, correlates with loss of tissue differ-
entiation  (high  histological  grade)  and  poor  patient 
prognosis.  This  suggests  that  in  breast  cancer,  the 
mechanisms driving CIN and loss of tissue differen-
tiation  are  determined  by  independent  centrosome 
defects  (structural  and  functional,  respectively), 
which may not be necessarily dependent on the ab-
sence of p53 function [38]. p53 loss may play a critical 
role in the generation of supernumerary centrosomes 
in breast cancer cells only following genotoxic stress 
or mitogenic stimulation through its abrogation of the 
G1/S  cell  cycle  checkpoint,  involving  a 
CDK2/cyclin-dependent pathway [39, 40]. In relation, 
CA and multinucleation are present in MCF7 cells as a 
result of cytokinesis failure, due to the expression of 
the low molecular isoform of cyclin E. This phenotype 
is  exacerbated  in  the  absence  of  p53  and  occurs 
via premature activation of cdc25C [41, 42]. 
 BRCA1  is  a  breast  and  ovary-specific  tumour 
suppressor that in association with BRCA1-associated 
RING  Domain  1  (BARD1),  acts  as  a  powerful  E3 
ubiquitin  ligase.  The  BRCA1-BARD1  complex, 
through the ubiquitination of gamma-tubulin, main-
tains  centrosome  homeostasis  by  prevention  of  its 
aberrant  reduplication  [43].  Inhibition  of  BRCA1 
causes rapid centrosome overduplication and possi-
bly fragmentation in human breast cell lines [43-45], 
as well as stimulates centrosome microtubule nuclea-
tion function [46]. Consistent with these reports, dis-
ruption of the BRCA1 gene in mice leads to CA and 
aneuploidy [47, 48]. Numerical centrosome aberration 
is  also  associated  with  negative  BRCA1  expression 
and  its  germline  mutations  in  human  breast  cancer 
specimens [37]. Overexpression of Ninein-like protein 
(Nlp),  a  BRCA1-associated  centrosomal  protein 
overexpressed in human breast cancers, is associated 
with CA in rodent fibroblasts as well as spontaneous 
breast tumourigenesis in transgenic mice, suggesting 
that  Nlp  overexpression  mimics  BRCA1  loss  [49]. 
NPM is a BRCA2-associated protein, which together 
with ROCK2 may form a complex that maintains the 
numerical integrity of centrosomes and accurate cell 
division. Dysfunction of this regulation might be in-
volved in the tumourigenesis of breast cancer through 
both centrosome overduplication and fragmentation 
[50]. 
 Overexpresson  of  Aurora-A  kinase,  a  centro-
some-associated serine/threonine kinase, and gain of 
its associated gene locus  on 20q13.2, leads to aneu-
ploidy,  cell  transformation,  and  CA  in  mammalian 
cells [51]. Aurora-A overexpression is associated with 
CA in DCIS [52] but not in IDC [37], suggesting that it 
may be more relevant in tumour initiation than pro-
gression. Correspondingly, Aurora-A overexpression 
and  CA  are  found  to  be  early  events  in  mammary 
tumour development in animal models [53, 54], which 
may  be  mediated  by  estrogen  exposure  [55].  The 
mechanism of CA triggered by Aurora-A may be in Int. J. Biol. Sci. 2011, 7 
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part due to cytokinesis failure, which is facilitated by 
its effects on promoting p53 degradation [56]. Auro-
ra-A-overexpressed  mice  display  CA,  tetraploidiza-
tion and premature sister chromatid segregation prior 
to  tumour  formation,  which  is  aggravated  by  hap-
loinsufficiency  of  p53.  The  severe  chromosomal  ab-
normality  did  not  cause  cell  death  due  to  the  con-
comitant activation of the pro-survival AKT pathway, 
allowing  continuous  proliferation  of  the  tetraploid 
cells  and  accumulation  of  centrosomes  [54].  On  the 
other hand, Aurora-A kinase is also known to inter-
fere  with  BRCA1  ubiquitin  ligase  function  though 
inhibitory phosphorylation [57], thereby also possibly 
promoting  centrosome  overduplication  and  frag-
mentation. MDC1 and BRIT1, both negative regula-
tors  of  Aurora-A  and  PLK1,  are  observed  to  be  in-
versely correlated with CA in human breast cancer. 
MDC1-depleted  cells  exhibit  centrosome  overdupli-
cation, whilst BRIT1 depletion leads to defective cy-
tokinesis and centrosome accumulation [58]. Similar 
to  Aurora-A  kinase  is  another  centrosomal  kinase 
Nek2  that  is  frequently  elevated  in  DCIS  and  IDC, 
which promotes the accumulation of supernumerary 
centrosomes via cytokinesis failure in breast epithelial 
cells [59]. Oncogenic k-ras but not c-myc initiates CA 
in  mammary  precursor  lesions.  Instead,  c-myc  in-
duces CA in tumours, pointing to a role for c-myc in 
tumour progression and k-ras in initiation. Abolishing 
the expression of CDK4/cyclin D1 or Nek2 abrogates 
Ras-induced CA in human mammary epithelial cells, 
whereas silencing cyclin E1 or B2 has no such effect 
[60], suggesting that Ras-evoked CA may be an early 
breast  oncogenic  event  that  occurs  through  a  Nek2 
and CDK4/cyclin D1-dependent pathway. 
Pin1, a prolyl isomerase implicated in the acti-
vation  of  multiple  oncogenic  pathways,  is  overex-
pressed and positively correlates with CA in human 
breast  cancer  tissue.  Additionally,  Pin1  localizes  to 
centrosomes in interphase but not mitotic cells in vitro. 
Overexpression  of  Pin1  induces  multiple  rounds  of 
centrosome duplication in S-phase arrested cell lines, 
resulting  in  formation  of  multipolar  mitoses,  chro-
mosomal missegregation, aneuploidy, and malignant 
transformation  [61].  Pin1  overexpression  in  mouse 
mammary glands induces CA, leading to mammary 
hyperplasia  and  malignant  tumours.  This  suggests 
that a mechanism of Pin1 overexpression and uncon-
trolled centrosome duplication cycles may contribute 
to  CA  in  breast  cancer  [61].  Y-box  binding  protein 
YB-1, which is overexpressed in 75% of human breast 
carcinomas, has been implicated in the generation of 
CA in breast cancers as well. In transgenic mice, YB-1 
expression  in  mammary  epithelial  cells  provokes 
breast  carcinomas  of  different  histologic  types 
through induction of CIN that emerges from mitotic 
failure and CA. Moreover, YB-1-evoked CA occurs in 
premalignant  lesions  and  proceeds  during  breast 
cancer development [62]. The mechanism underlying 
CA  in  YB-1-dependent  breast  cancer  development 
probably occurrs through cytokinesis failure induced 
by LIMK mislocalization, and is independent of p53 
and pRb deregulation [63]. Several other mechanisms 
implicated in the generation of CA in breast cancer 
include  the  aberrant  expression  of  LMO4  [64],  cen-
trosome  overduplication  via  nuclear  expression  of 
endogenous  aryl  hydrocarbon  receptor  (AhR)  and 
cyclin E [65], as well as cell fusion following ectopic 
expression of the RAD6 ubiquitin conjugating enzyme 
[15].  
Urogenital cancer 
Prostate cancer 
 Support for CA contributing to genomic insta-
bility during prostate cancer development has been 
derived from data showing the increased frequency of 
centrosome abnormalities progressing from prostate 
intraepithelial neoplasia (PIN) to non-metastatic and 
metastatic  cancers,  with  the  extent  of  defects  corre-
lating with the degree of CIN. Intra-tumoural centro-
some  abnormalities  are  also  more  severe  and  less 
variable in metastatic tumours than those in localized 
prostatic carcinoma. Centrosome size and number, as 
well as pericentrin levels are greater in high Gleason 
grade tumours,  which correlates with the  more ad-
vanced extent of CIN in these lesions [10, 28, 66, 67]. In 
support of these findings, artificial induction of cen-
trosome  abnormalities  in  cultured  prostate  cells  by 
overexpression of the centrosome protein pericentrin 
reproduces  many  features  of  aggressive  prostate 
cancer. Overexpression of pericentrin induces severe 
centrosome and spindle defects, cellular disorganiza-
tion,  genomic  instability  and  enhances  growth  in 
prostate epithelial cell lines [66]. There is evidence to 
support a role for cytokinesis defects in the generation 
of CA in prostate cancer. Overexpression of oncogenic 
kinase PIM-1 in prostatic epithelial cells leads to the 
development of mitotic spindle defects, multinuclea-
tion,  and  supernumerary  centrosomes  [68]. 
Non-functional  p53  also  promotes  the  formation  of 
increased  centrosome  number  and  size  in  prostate 
cancer cell lines by abrogating the G2/M checkpoint 
control [69]. 
Urothelial cancer 
In transitional cell carcinoma (TCC) of the uri-
nary tract, CA is associated with CIN and aneuploidy 
[70-75], but not with MIN - tumours with low expres-
sion of MLH1 or MSH2 mismatch repair proteins are Int. J. Biol. Sci. 2011, 7 
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not linked with CA [73]. Interestingly, coalesence of 
multiple  centrosomes  into  two  functional  spindle 
poles  occurs  in  80%  of  chromosomally-unstable 
bladder tumours, suggesting that this may be an im-
portant mechanism limiting the deleterious effects of 
multipolar  mitoses  on  the  cancer  cells  [75].  Several 
studies have found an association of centrosome ab-
erration with clinical prognostic indicators, including 
high histological grade [70-72, 74, 76]. CA correlates 
with  recurrence-free  survival  and  progression-free 
survival,  and  is  the  strongest  predictor  for  tumour 
recurrence in non-muscle invasive urothelial cancers 
of the bladder [72, 73]. However, no association with 
recurrent disease, distant metastasis or cause-specific 
death  was  demonstrated  in  another  study  on  renal 
and ureteric urothelial cancers [74]. Collectively, this 
may  suggest  the  presence  of  two  distinct  types  of 
urothelial  cancers  classified  according  to  genomic 
instability:  i)  MIN  cancers  that  show  relatively  fa-
vourable prognosis and ii) CIN cancers with CA that 
display highly malignant behaviour. 
Like in breast cancers, the association of CA with 
20q13.2  copy  number  gain  and  Aurora-A  kinase 
overexpression has been reported in urothelial carci-
noma, specifically in those harbouring CIN and an-
euploidy rather than MIN [72-74, 77]. Forced overex-
pression of Aurora-A in urothelial cells induced CA, 
chromosome  missegregation  and  aneuploidy  [77]. 
Bladder  cancer  cell  lines  harbouring  Aurora-A  and 
p53  overexpression  display  supernumerary  centro-
somes  with  an  even  number  of  chromosome  copy 
number [78]. In clinical studies, CA in bladder TCC 
specimens  strongly  correlates  with  concomitant  oc-
currence of cyclin E overexpression and p53 inactiva-
tion [76], as well as cyclin D1 gene amplification [75]. 
Other proteins like PLK-1 and BUBR1 have been as-
sociated  with  CA,  CIN  and  aneuploidy  in  bladder 
cancer  as  well,  but  their  significance  remains  to  be 
explored [79, 80]. Overall, a cooperative mechanism 
for CA in bladder cancers is suggested through both 
disinhibition of centrosome duplication (as a result of 
cyclin E and/or cyclin D overactivity) and cytokinesis 
failure (as a result of p53 mutation and/or Aurora-A 
overexpression). 
Renal and adrenal tumours 
In  renal  cell  carcinoma  (RCC),  centrosome  ab-
normalities and mitotic multipolarity are present in 
the subgroup displaying complex karyotypes. Inter-
estingly, telomeric dysfunction and anaphase bridges 
are concomitantly observed in this subgroup of can-
cers, indicating the presence of two possibly related 
mechanisms i.e. CA and telomeric dysfunction, in the 
generation of genetic instability of RCC [81]. There is 
also  a  possibility  that  CA  is  a  result  of  cytokinetic 
failure  from  repeated  chromosomal  break-
age-fusion-bridge cycles, due to mechanical blocking 
of cytokinesis by anaphase bridges. Overexpression of 
miR-210, a downstream target of HIF1α, has recently 
been  reported  to  evoke  CA  and  multipolar  spindle 
formation in renal carcinoma cells [82]. CA has also 
been reported in adrenocortical adenomas and carci-
noma [83]. 
Cervical cancer 
 The  mechanisms  underlying  CA  in  high-risk 
human  papillomavirus  (HPV)-associated  cervical 
carcinogenesis has been extensively studied over the 
past  decade.  Centrosome  aberration  has  been 
demonstrated in cervical dysplasia and invasive cer-
vical  carcinoma,  most  of  which  are  aneuploid  and 
positive for high-risk HPV infection [10]. CA is also 
associated  with  spindle  defects  and  correlates  posi-
tively  with  increasing  grade  of  dysplasia,  and  is 
highest  in  lesions  of  invasive  carcinomas  [84].  Fur-
thermore, CA is detected in organotypic raft cultures 
of human keratinocytes containing episomal HPV-16 
DNA, even in basal cells with low copy numbers of 
HPV-16 genome [85], supporting its involvement in 
tumour initiation and progression. 
 In high-risk HPV-associated cervical carcinoma, 
a collaborative effort by the HPV-encoded oncopro-
teins E6 and E7 have been implicated in the genera-
tion  of  supernumerary  centrosomes  and  multipolar 
mitoses,  predisposing  to  CIN  and  carcinogenesis. 
Whilst stable expression of E6 or E7 in primary hu-
man  keratinocytes  results  in  abnormal  centrosome 
numbers [13], co-expression results in an even higher 
number  of  cells  with  supernumerary  centrosomes 
[86].  In  addition,  although  acute  expression  of  E7 
alone rapidly induces abnormal centrosome numbers, 
that of E6 alone has no such effect [13]. In a transgenic 
mouse model of estrogen-induced carcinogenesis, E7 
alone  is  sufficient  to  evoke  CA,  producing  both 
high-grade  cervical  dysplasia  and  invasive  cervical 
malignancies.  E6  alone  elevates  centrosome  copy 
number  but  do  not  produce  cancer  in  the  mice. 
However, E6 plus E7 additionally elevate centrosome 
copy  number  and  create  large,  extensively  invasive 
cancers, supporting the cooperative mechanism [87]. 
 E7  drives  the  generation  of  abnormal  centro-
some  numbers  by  directly  interfering  with  centro-
some  duplication  control.  E7  expression  rapidly  in-
creases  daughter  centriole  formation  in  otherwise 
normal diploid cells within a single cell division cycle 
prior to the development of extensive genomic insta-
bility [13, 88]. This rapid mode of centriole overdu-
plication has been demonstrated to proceed through a Int. J. Biol. Sci. 2011, 7 
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pathway characterized by a single maternal centriole 
initiating the simultaneous synthesis of two or more 
daughter centrioles, necessitating CDK2/cyclin activ-
ity  and  PLK4  upregulation  [89-91]  as  well  as  RNA 
polymerase  II  transcription  [92].  The  absolute  re-
quirement of CDK2 dysregulation is consistent with 
the known effects of E7 on pRB inactivation [93] and 
the  resultant  release  of  E2F  transcription  factors  as 
well  as  upregulation  of  CDK2/cyclin  E  activity 
needed for S phase entry. Interestingly, although a E7 
deletion  mutant  lacking  pRB  binding/degradation 
properties is unable to induce centriole overduplica-
tion [13], wild-type E7 is able to induce centriole ab-
normalities  in  pRB/p107/p130-deficient  cells  [94], 
implying that pRB degradation is not the only mech-
anism  by  which  oncogenic  E7  induces  centriole 
overduplication.  This  pRB/p107/p130-independent 
mechanism has been suggested to be contributed by 
the association of E7 with gamma-tubulin [95]. 
 On the other hand, unlike E7, E6 probably does 
not affect centrosome duplication, but instead allows 
for centrosome accumulation over a prolonged period 
of time in genomically-unstable cells. This centrosome 
accumulation  occurs  in  parallel  with  nuclear  atypia 
(e.g.  multi-nucleation,  micronuclei).  Whilst  many  of 
these cells display features of replicative senescence 
which  are  unlikely  to  proliferate  further  [88],  there 
remains  the  likelihood  of  some  polypoidal  cells  es-
caping senescence and successfully completing mito-
sis,  leading  to  the  propagation  of  genomical-
ly-unstable progeny. Such abnormal cells would have 
avoided mitotic arrest or apoptosis since E6 interferes 
with  p53-dependent  checkpoints  by  triggering  the 
proteasomal degradation of p53 [96]. The involvement 
of E6 in the early stages of cervical carcinogenesis is 
supported by studies demonstrating the presence of 
centrosome abnormalities in raft cultures harbouring 
genomes mutated in E7 expression [85]. Moreover, the 
HPV-16 E2 protein that is required for early viral rep-
lication inhibits E7 but not E6-triggered CA [97]. In-
triguingly, E2 promotes G2/M arrest independent of 
E6 and E7, characterized by the accumulation of active 
CDK/cyclin B1 complexes and histone H3 phosphor-
ylation,  followed  by  metaphase-specific  apoptosis. 
E2-expressing cells which spontaneously escape arrest 
and  apoptosis  display  CA  and  CIN  [98].  Taken  to-
gether, it may be speculated that in the early stages of 
HPV-induced  cervical  carcinogenesis,  centrosome 
accumulation triggered by E6 and/or E2 may be the 
predominant  mechanisms  for  the  generation  of  su-
pernumerary  centrosomes;  in  the  later  stages,  it  is 
possible that the loss of E2 may then permit E7 to take 
on a predominant role through centrosome overdu-
plication,  whilst  E6  takes  on  a  cooperative  role  by 
creating a permissive milieu for genomic disintegrity 
and centrosome accumulation, through the relaxation 
of p53 checkpoint control. 
 Interestingly, recent evidence suggests that gen-
ital infection by Chlamydia trachomatis may contribute 
to HPV-induced cervical cancer formation through its 
disruptive effects on centrosome homeostasis. Similar 
to  high-risk  HPV,  chlamydial  infection  triggers  the 
production  of  supernumerary  centrosomes  and 
chromosome segregation defects which persist even 
after cells are cured with antibiotics [99]. The under-
lying  mechanism  possibly  involves  abortive  cytoki-
nesis,  but  centriole  overduplication  through  CDK2 
and  PLK4-dependent  pathways  appear  to  be  pre-
dominant [100]. Additionally, CA is exacerbated by 
chlamydial  infection  via  an  increase  in  centrosome 
spread and inhibition of the spindle assembly check-
point  delay  to  disrupt  centrosome  clustering  [101]. 
This  latter  phenomenon  may  interfere  with  centro-
some clustering in HPV-infected cells, thereby facili-
tating multipolar mitosis and CIN. 
Ovarian and testicular cancers 
In  ovarian  adenocarcinoma,  near-tetraploid  tu-
mours, which display greater numerical CIN, possess 
a  higher  degree  of  intratumoural  CA;  whereas 
near-diploid  tumours  show  fewer  abnormal  centro-
somes and comparatively lower numerical but higher 
degrees of structural CIN [102, 103]. This implicates 
upon two distinct but possibly  inter-related mecha-
nisms for the generation of chromosomal aberration 
in ovarian carcinoma – one via copy-number instabil-
ity associated with mitotic segregation abnormalities, 
cytokinesis  errors  and  CA,  and  the  other  through 
structural  change  possibly  as  a  result  of  impaired 
DNA repair [103]. Of clinical relevance, the prognostic 
significance of CA in ovarian cancer is demonstrated 
by  its  association  with  higher  stage,  histological 
grade, and the more aggressive serous-type compared 
to endometroid-type tumours [102]. In testicular germ 
cell  tumours,  those  with  aneuploidy  are  frequently 
associated  with  CA.  Aneuploid  seminomas  and 
non-seminomas (including carcinoma-in-situ and in-
fantile yolk sac tumours) show increased numbers of 
centrosomes.  In  contrast,  the  occurrence  of  CA  in 
diploid infantile teratomas is less frequent [104]. 
High Aurora-A kinase expression strongly asso-
ciates with supernumerary centrosome count in pri-
mary ovarian tumour cells but not in testicular germ 
cell tumours [104], and is an independent predictor of 
decreased  survival  in  ovarian  cancer  patients  [105]. 
Interestingly, HeyA8-MDR cells are more aggressive 
and  chemoresistant  compared  to  their  parental 
HeyA8 cells, and their Aurora-A expression and cen-Int. J. Biol. Sci. 2011, 7 
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trosome count are significantly higher as well [105]. In 
relation, Aurora-A overexpression in ovarian cancer 
cell lines promotes CA, malformation of mitotic spin-
dles and chromosome aberration. At the same time, 
Aurora-A suppresses the expression of p21, pRb, and 
BRCA2 to advance cell cycle progression and to abol-
ish  cellular  apoptosis  and  DNA  damage  re-
sponse [106]. Ectopic expression of Aurora-A kinase 
renders ovarian cancer cells resistant to drug-evoked 
apoptosis by activating the AKT survival pathway in 
a p53-dependent manner [107]. Taken together, this 
may suggest that poor outcome in ovarian cancer pa-
tients with Aurora-A kinase overexpression and CA 
may be a result of concomitant chemoresistance. 
Gastrointestinal cancer 
Colorectal carcinoma 
 CA is detected in as early as low-grade dysplas-
tic lesions of the colorectal adenoma-adenocarcinoma 
sequence [10, 108, 109], is more frequent in carcinoma 
compared to adenoma, and is associated with higher 
histological grade of both dysplastic as well as inva-
sive lesions [109], supporting its roles in the initiation 
and progression of colorectal cancer (CRC) develop-
ment. In CRC cell lines, the occurrence of CA lies ex-
clusively in aneuploid but not diploid tumours, cor-
relating with severe impairment of microtubule nu-
cleation ability and chromosome segregation errors in 
the aneuploid cell lines [110]. These in vitro observa-
tions  correspond  with  findings  in  primary  human 
tissue that defects in centrosome organization, spindle 
structure,  and  chromosome  segregation  often  occur 
within the same tumour cells, correlating with CIN 
and presence of aberrant nuclei [10]. 
In addition to the association with aneuploidy, a 
proportion  of CRC cell lines with CA also contains 
p53  mutations  or  overexpression,  gains  or  genomic 
amplification of 20q, as well as increased copies of 16p 
[110]. Ectopic overexpression of Aurora-A kinase in 
HCT116  cells  leads  to  supernumerary  centrosomes 
and aneuploidy regardless of p53 status [111]. In the 
same cell line, oncogenic beta-catenin is also required 
for  S-phase  arrest  and  centrosome  overduplication 
[112], whilst insufficient PLK4 is associated with ab-
errant centrioles [113]. Loss of hSgo1, a protein regu-
lating chromosome segregation that is downregulated 
in CRC, results in G2/M arrest and apoptosis, while 
promoting CIN and CA, cytokinesis defects and mi-
totic  catastrophe  [114].  Telomerase  transcriptional 
elements-interacting  factor  (TEIF),  a  centro-
some-associated protein and transactivator of human 
telomerase reverse transcriptase subunit (hTERT), is 
overexpressed in colorectal adenoma and CRC com-
pared to normal tissue, and positively correlates with 
CA and tumour grade [109], suggesting that telomere 
dysfunction may be responsible for generation of CA 
in CRC. At the same time, it is also possible that both 
telomere dysfunction and CA contribute separately to 
genomic instability in CRC. 
Esophageal cancer 
In cases of chronic esophagitis followed by Bar-
rett's metaplasia-derived adenocarcinoma, CA is fre-
quently  observed  in  both  Barrett's  metaplasia  and 
adjacent histopathologically-normal native squamous 
epithelium. Interestingly, centrosome aberrancies are 
less frequent in frank adenocarcinoma compared to 
Barrett's  metaplasia,  perhaps  suggesting  its  relative 
importance in earlier stages of carcinogenesis [115]. 
Hepatobiliary cancer 
 CA  may  play  a  role  in  the  initiation  and  pro-
gression of biliary cancers. Biliary tumours including 
gallbladder  cancers  (GC),  intrahepatic  cholangiocel-
lular  carcinomas  (CCC),  and  extrahepatic  bile  duct 
cancers (BDC) display CA. CA also occurs in chronic 
cholecystitis and hepatolithiasis, both potentially ne-
oplastic conditions. In addition, advanced stage can-
cers possess a higher frequency and greater levels of 
CA than in the early stages [116]. 
 In  hepatocellular  carcinomas  (HCC),  intra-
tumoural  CA  is  significantly  higher  in  non-diploid 
tumours  than  in  diploid  tumours.  CA  is  associated 
with p53 mutation but is not related to tumour stage, 
size  or  proliferative  activity  [117].  The  upstream 
mechanisms leading to CA in HCC have been inves-
tigated  in  in  vitro  models  of  hepatitis  B  virus 
(HBV)-associated  hepatocarcinogenesis.  Specifically, 
the HBV-encoded hepatitis B virus X (HBX) oncopro-
tein promotes centrosome overduplication and cyto-
kinesis  defects  through  its  interaction  with  cellular 
protein HBXIP [118, 119]. Additionally, HBX evokes 
centrosome overduplication, multipolar spindles and 
aneuploidy  through  cytoplasmic  sequestration  and 
inactivation of Crm1, a Ran-GTP binding nuclear ex-
port  receptor  [120],  as  well  as  by  activating  the 
Ras-MEK-MAP kinase pathway [121]. 
Pancreatic cancer 
 CA  is  detected  in  primary  pancreatic  exocrine 
tumours, including both ductal carcinomas and ade-
nomas [122], as well as in pancreatic cancer cell lines, 
particularly those with multipolar spindles, defective 
mitoses and CIN [123]. Interestingly, although CA is 
prevalent in exocrine tumours, endocrine malignan-
cies show normal centrosome patterns and thus may 
arise through different genomic instability pathways Int. J. Biol. Sci. 2011, 7 
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[122]. Using orthotopic transplantation of Suit-2 hu-
man pancreatic carcinoma cells into nude mice as a 
model,  supernumerary  centrosome  numbers  are 
found at higher frequencies in metastatic foci than in 
pancreatic  xenografts,  correlating  with  multipolar 
mitotic  spindles  and  enhanced  degree  of  CIN [124]. 
Aurora-A kinase is amplified in pancreatic cancer cell 
lines and primary pancreatic cancer [125], and is as-
sociated with CA, giant nuclei formation and CIN in 
vitro [126]. Taken together, this supports cytokinesis 
failure as a major mechanism underlying CA in pan-
creatic cancer. Cytokinesis failure and the tendency of 
p53-proficient binuclear and tetraploid cells to evade 
the tetraploidy checkpoint are commonly observed in 
an acinar-ductal transdifferentiating culture model of 
pancreatic carcinogenesis, predisposing to pleiotropic 
mitotic defects. In the context of p53 deficiency, un-
controlled polyploid progression ensues due to eva-
sion of the tetraploidy checkpoint during cytokinesis 
failure,  leading  to  a  rapid  exacerbation  of  CA  and 
aneuplody [127]. 
Lung cancer 
 CA  has  been  demonstrated  in  a  proportion  of 
lung cancers, including squamous cell carcinoma and 
adenocarcinoma  [10,  128,  129],  and  correlates  with 
aneuploidy.  However,  there  is  no  significant  rela-
tionship with clinical characteristics such as tumour 
size, disease stage, or patient survival [129]. In human 
lung cancer tissue, CA positively correlates with loss 
of pRb expression as well as with E2F1 and cyclin E 
overexpression [128, 129]. At least some cells with CA 
ars also positive for p53 mutation, although correla-
tive significance is absent [128-130]. The possible as-
sociation  of  p53  loss  with  centrosome  anomalies  is 
supported by studies on p53-knockout murine bron-
chiolar epithelial “Clara” cells, presumably the origin 
of  lung  adenocarcinoma,  which  possess  increased 
centrosome  number  and  multinucleation,  as  com-
pared  to  their  wild-type  p53  counterparts  [131].  In 
addition,  several  studies  have  demonstrated  a  rela-
tionship between exposure to carcinogens implicated 
in  lung  cancer  and  the  development  of  centrosome 
abnormalities in vitro. Specifically, exposure to chrys-
otile  asbestos  fibres  [132],  chromate  particles  [133, 
134],  arsenite  [135,  136]  and  benzo[a]pyrene  diol 
epoxide [137] have been shown to induce CA, multi-
polar  spindles,  aneuploidy,  as  well  as  malignant 
transformation in human lung cell lines, which may 
be conditional on p53 dysfunction. Expression of Skp2 
in  lung  cancer  cells  is  associated  with  CA  as  well 
[138].  Recently,  NORE1A,  a  gene  commonly  down-
regulated  in  non-small  cell  lung  cancer,  has  been 
shown  to  suppress  CA  induced  by  hydroxyurea  in 
lung cancer cell lines, implying a preventive role of 
NORE1A  against  carcinogenesis  of  non-small  cell 
lung cancer [139]. 
Neural cancer 
 CA  has  been  demonstrated  in  several  neural 
cancers  [10],  including  aneuploid  cerebral  primitive 
neuroectodermal tumours (PNET) with p53 mutation 
[140], diffuse astrocytic gliomas of various histological 
grades [141], pituitary adenomas (PA) [142], as well as 
in medulloblastoma [143]. Gamma-tubulin staining is 
greater in adult  high grade anaplastic astrocytomas 
and glioblastomas as compared to low-grade diffuse 
astrocytomas  [141].  Similarly,  supernumerary  cen-
trosomes as well as higher Aurora-A mRNA expres-
sion  levels  are  observed  in  high  grade  but  not  low 
grade  glioma  [144].  Comparing  with  normal  brain 
tissue, mRNA expression  for centrosomal structural 
proteins, such as centrin 3, gamma-tubulin, hNinein 
isoforms  1/2/5/6,  Aurora-A  and  Aurora-B  are  ele-
vated  in  glioma  tissue  [144].  Survivin  suppression 
leads to CA in glioma cell lines, especially in the ab-
sence of p53 [145]. Loss of PTEN and expression of 
EGFRvIII  transform  neural  precursor  cells  into  tu-
mours  resembling  glioblastomas,  displaying  CA, 
Aurora-A/B  upregulation,  and  activation  of 
Ras/Erk/AKT  pathways  [146].  Interestingly,  vari-
ously  pronounced  gamma-tubulin  localization  is 
present in the cytoplasm of vascular endothelial cells 
in areas of tumour angiogenesis (microvascular pro-
liferation) in glioblastomas [141]. This indicates that 
CA  may  underlie  neoplastic  neovascularization  in 
glioblastomas. In support of this notion, endothelial 
cells in solid tumours are aneuploid and are curiously 
associated with multiple centrosomes as well [147]. 
 In PA, CA is observed in somatotroph and lac-
totroph adenomas, which are characterized by aneu-
ploidy and securin overexpression, in comparison to 
non-functioning adenomas or normal pituitary tissue 
[142]. In a mouse study, forced transgenic expression 
of cyclin E in the pituitary intermediate lobe results in 
CA  [148].  In  medulloblastoma,  overexpression  of 
gamma-tubulin is widespread in poorly differentiat-
ed, proliferating tumour cells but is significantly di-
minished  in  quiescent  differentiating  tumour  cells 
undergoing  neuritogenesis  [143].  In  primary  neuro-
blastoma tumours, childhood and infant diploid tu-
mours  display  greater  CA  than  infant  triploid  tu-
mours.  Ploidy  divergence  accompanying  tetraploid 
cells,  implying  cytokinesis  failure,  occurs  very  fre-
quently  in  infant  diploid  but  not  infant  triploid  tu-
mours. However, although CA is found in the major-
ity of childhood diploid tumours, none of these show 
ploidy  divergence,  suggesting  centrosome  overdu-Int. J. Biol. Sci. 2011, 7 
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plication  as  the  mechanism  of  CA  in  this  group  of 
tumours  [149].  CA  may  be  associated  with  MYCN 
locus  amplification  in  primary  neuroblastoma  [149, 
150].  This  is  supported  by  in  vitro  observations, 
whereby in neuroblastoma cell lines, MYCN overex-
pression induces CA in response to a DNA damage 
stimulus  such  as  ionizing  radiation  [150, 151]. Sup-
pression of p27 expression through increased expres-
sion of Skp2 [152], as well as MDM2-mediated nega-
tive regulation of p53 activity [150] may underlie this 
DNA damage-evoked CA. 
Head and neck cancer 
 CA has been observed in squamous cell carci-
nomas of the head and neck (HNSCC) [153-159], be-
nign salivary gland pleomorphic adenomas [155], as 
well  as  in  thymic  carcinoid  tumour  [160].  Strong 
prognostic  implications  have  been  demonstrated  in 
HNSCC.  High  intratumoural  CA  is  associated  with 
local  tumour  recurrence  of  surgically-resected  oral 
SCC  despite  histologically-negative  margins.  Inter-
estingly, analysis of the tumour margins for CA found 
a  trend  toward  local  tumour  recurrence  in  patients 
whose margins showed high degree of CA [154]. CA 
is also observed in oral epithelial dysplasia. The per-
centage of cells containing CA is more frequent in oral 
SCC than dysplasia, as well as in poorly-differentiated 
oral SCC relative to moderate- and well-differentiated 
subtypes [158]. Collectively, this strongly implicates 
upon CA as a major mechanism driving the initiation 
and progression HNSCC. In laryngeal SCC, presence 
of cells with large centrosomes is a better predictor of 
tumour  recurrence  compared  to  T  stage,  and  even 
predicts  recurrence  in  node-negative  tumours. 
Moreover,  this  group  of  patients  shows  a 
near-significant  trend  for  shorter  survival  and  thus 
poor prognosis [159]. In another study, CA is associ-
ated with tumour size, stage, distant metastasis, dis-
ease-free survival and overall survival [157]. 
 There is evidence to support cytokinesis failure 
as the major mechanism underlying CA in HNSCC, 
which  may  involve  Aurora-A  kinase  upregulation 
[156], MDM2-p53 dysregulation [153], and decreased 
myosin light chain phosphorylation [161]. Aurora-A 
kinase  mRNA  and  protein  upregulation  are  fre-
quently occurring in HNSCC and are associated with 
CA and poor patient prognosis [156]. The underlying 
mechanism linking Aurora-A kinase overexpression 
and CA remains unclear, but its interaction with im-
portant cell cycle regulators such as p53 may be con-
tributory.  Notably,  Aurora-A  kinase  is  known  to 
phosphorylate  and  promote  the  MDM2-mediated 
degradation of p53 [56]. In earlier studies, CA have 
been correlated with the occurrence of either muta-
tion/deletion  of  p53.  Interestingly,  in  tumours  that 
retained wild-type p53, CA is associated with MDM2 
overexpression  instead  [153].  In  corroboration  with 
these  findings,  Swiss  3T3  cells  overexpressing  sta-
bly-transfected MDM2 show extensive CA and CIN, 
despite retaining wild-type p53 [153]. The actual rela-
tionship  between  Aurora-A  kinase  and  the 
MDM2-p53  pathway  in  generating  CA  in  HNSCC 
remains to be further elucidated.  
Dysfunctional telomeres have been suggested to 
play  a  possible  role  in  the  generation  of  CA  in 
HNSCC.  HNSCC  and  benign  salivary  gland  pleo-
morphic adenomas displaying abnormal karyotypes 
showed widespread centrosome aberration and mul-
tipolar division, together with anaphase bridges. The 
frequency of anaphase bridges correlates with num-
ber  of  chromosome  ends  lacking  TTAGGG  signals, 
indicating the presence of telomere shortening. This 
repeated chromosomal breakage-fusion-bridge cycles 
has  been  proposed  to  prevent  normal  cytokinesis, 
leading to centrosome accumulation along with mul-
tinucleation, multipolar cell division, and aneuploidy 
[155]. These cells however, may be at an evolutionary 
dead-end with limited contribution towards tumour 
development, since mitoses with five or more poles 
are very rarely observed [155]. 
Bone and soft tissue tumour 
Bone and soft tissue sarcoma 
 CA has been detected in various types of ma-
lignant and borderline malignant sarcomas, including 
osteosarcoma,  chondrosarcoma,  malignant  fibrous 
histiocytoma (MFH), haemangiopericytoma, atypical 
lipomatous tumour, liposarcoma, giant cell  tumour, 
peripheral  PNET,  synovial  sarcoma,  rhabdomyosar-
coma, leiomyosarcoma as well as malignant periph-
eral nerve sheath tumour (MPNST) [162-167]. In sev-
eral  types  of  sarcomas,  aneuploid  karyotypes  are 
strongly associated with supernumerary centrosomes 
and multipolar mitoses, as well as anaphase bridges. 
Furthermore, supernumerary centrosomes and mul-
tipolar  mitoses  are  positively  correlated  with  ana-
phase  bridges,  supporting  both  types  of  abnormal 
chromosome segregation in the evolution of CIN in 
these soft tissue sarcomas [164]. A small study of six 
well-differentiated liposarcomas of both near-diploid 
(Type  D)  and  near-tetraploid  (Type  H)  cytogenetic 
subtypes  display  CA,  independent  of  their  ploidy 
status, although Type H tumours demonstrate higher 
intratumoural degrees of centrosome number short of 
statistically significance [165]. 
 Numerical  CA  is  more  frequently  observed  in 
highly aggressive types of sarcomas, including PNET, Int. J. Biol. Sci. 2011, 7 
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synovial  sarcoma,  rhabdomyosarcoma,  MFH,  as 
compared to moderate grade sarcomas such as lipo-
sarcoma and leiomyosarcoma [166]. The degree of CA 
is also significantly higher in recurrent and malignant 
cases than in non-recurrent cases of giant cell tumour 
of bone  [167], in which a positive correlation exists 
between aneuploidy and CA. Interestingly, benign or 
tumour-like lesions of soft tissue may also feature CA, 
albeit at lower frequencies [164-166]. 
 Analysis of p53-mutant osteosarcoma cell lines 
reveals  a  wide  range  of  aneusomy,  high  levels  of 
atypical mitotic figures, and high frequencies of ab-
normal  centrosome  numbers,  as  compared  to  p53 
wild-type cell lines [163]. Furthermore, treatment with 
colcemid, a spindle-disrupting polyploidizing agent, 
induces multipolar cell division and supernumerary 
centrosomes  in  an  MDM2-amplified  osteosarcoma 
cell line but not in normal fibroblasts [164]. This may 
implicate a defective p53 pathway in the generation of 
centrosome aberration and CIN in osteosarcoma. 
 Similar to earlier reports in colorectal adenoma 
and CRC [109], TEIF positively correlates with CA in 
soft tissue sarcomas, and is related to tumour grade 
[166]. In addition, in vitro overexpression of TEIF lev-
els  either  exogenously  introduced,  or  evoked  by 
DNA-damaging  agents  or  telomeric  dysfunction 
promotes  multinucleation,  CA,  mitotic  defects,  and 
chromosome  missegregation  [166].  Collectively,  this 
suggests that DNA damage evokes TEIF centrosomal 
expression, resulting in CA and genomic instability 
that contributes to tumour progression. 
Kaposi sarcoma 
 The  Kaposi  sarcoma-associated  herpes  virus 
(KSHV) has been linked with several human malig-
nancies,  including  all  subtypes  of  Kaposi  sarcoma, 
primary  effusion  lymphoma,  and  multicentric  Cas-
tleman  disease.  Kaposi  sarcoma  lesions  are  latently 
infected by KSHV and express latent genes, such as 
KSHV cyclin (K cyclin) and latency associated nuclear 
antigen  (LANA).  Expression  of  K  cyclin  in  human 
endothelial cells induces senescence and strong DNA 
damage response, leading to CA and S-phase arrest 
through a CDK6 and ATM-Chk2-dependent pathway 
[168].  In  human  and  mouse  primary  fibroblasts,  K 
cyclin expression results in a p53-dependent growth 
arrest, abortive cytokinesis and centrosome accumu-
lation  [169].  In  the  absence  of  p53,  the  K  cy-
clin-induced CA is exacerbated, leading to the acqui-
sition of an aneuploid population of cells which is not 
only genetically unstable but also resistant to apopto-
sis [169]. In line with these findings,  in vivo studies 
demonstrated  accelerated  K  cyclin-induced  lym-
phomagenesis  in  mice  without  p53  [170].  Notably, 
KSHV infection of endothelial cells generates super-
numerary  centrosomes  and  multinucleation  [168, 
171],  suggesting  that  the  hindrance  of  tumour  pro-
gression  due  to  p53-triggered  growth  arrest  and 
apoptosis  may  be  overcome  by  other  latent  viral 
genes. Indeed, LANA is able to bind p53 and inhibits 
the ability of p53 to transactivate cellular genes, re-
sulting in abnormal centrosomes, multinuclear cells, 
and  other  genomic  abnormalities  [172].  In 
KSHV-infected  cells,  NPM1  is  a  phosphorylation 
substrate  for  CDK6/K  cyclin  necessary  for  centro-
some duplication, and p53-driven apoptosis occurring 
downstream  of  NPM1  phosphorylation  is  a  critical 
checkpoint mechanism that prevents accumulation of 
cells with supernumerary centrosomes, which may be 
overcome by LANA co-expression [173]. 
Centrosome amplification in haematologi-
cal malignancies 
 In addition to solid neoplasms, centrosome ab-
errations are common in several haematological ma-
lignancies  including  Hodgkin's  (HL)  as  well  as 
non-Hodgkin's lymphomas (NHL), acute (AML) and 
chronic  myeloid  leukaemias  (CML), 
HTLV-1-associated adult T-cell leukaemia (ATL) and 
multiple myeloma (MM). In analogy to solid tumours, 
a correlation between CA and CIN as well as clinical 
aggressiveness  also  exists  in  certain  haematological 
malignancies [174]. 
Non-Hodgkin's and Hodgkin's lymphoma 
 Centrosome defects, predominantly structural in 
nature, are frequently detected in several subtypes of 
B-cell  lineage  NHL  including  diffuse  large  B-cell 
lymphoma (DLBCL), mantle cell lymphoma (MCL), 
Burkitt's  lymphoma  (BL), follicular  lymphoma  (FL), 
marginal zone B-cell lymphomas (MZBCL), as well as 
chronic lymphocytic leukaemia (CLL) [175, 176]. Sim-
ilar  abnormalities  occur  in  Hodgkin  and 
Reed-Sternberg (HRS) cells in classic HL [177, 178]. 
 Aggressive lymphomas like DLBCL, MCL and 
BL harbour more centrosome abnormalities than in-
dolent lymphomas including FL and MZBCL. In ac-
cordance,  the  degree  of  CA  is  associated  with  the 
proliferation/mitotic index, irrespective of histologi-
cal  subgroup  (FL,  DLBCL  and  MCL).  In  FL,  the 
number  of  cells  with  CA  correlates  with  increased 
histological grading; whilst in MCL, CA occurs at a 
higher  frequency  in  blastoid  variants  harbouring 
near-tetraploid chromosome numbers as compared to 
the less aggressive diploid subtypes [175]. In contrast, 
the latter correlation is not seen in FL and DLBCL. The 
significance of the centrosome in MCL subtyping and 
prognostication  is  further  supported  by  a  gene  ex-Int. J. Biol. Sci. 2011, 7 
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pression  signature  inclusive  of  centrosome  proteins 
CAMKK2, PCNT2, TUBGCP3 and TUBGCP4, which 
discriminated  between  near-tetraploid  and  diploid 
MCL [179]. Centrosome abnormalities are observed in 
B cell CLL and even at the premalignant monoclonal 
B-cell lymphocytosis (MBL) stage. The extent of CA 
correlates with the clinical aggressiveness and prolif-
erative  activity  of  the  CLL  cases  as  measured  by 
lymphocyte doubling time as well as with time to first 
treatment [176]. However, there is no correlation with 
IgVH gene mutation status or cytogenetically-defined 
risk  groups  (11q22-23,  17p13  and  13q14  deletions; 
trisomy 12). This is corroborated with the finding that 
no difference exists between CLL subgroups with or 
without  the  same  specific  chromosome  aberrations 
with prognostic significance [180]. 
Apart  from  B-cell  neoplasms,  numerical  and 
structural  centrosome  aberrations  are  present  in 
ALK-positive anaplastic large cell lymphoma (ALCL) 
as well, a T-cell derived neoplasm characterized by 
t(2;5) rearrangements, resulting in the creation of fu-
sion genes involving the ALK locus [181]. No correla-
tion between CA and p53 status is apparent in ALCL. 
Despite the prevalence of CA, ALK-positive ALCL is 
known  to  be  relatively  chromosomally  stable,  with 
only few secondary abnormalities on top of the pri-
mary  t(2;5)  or  variant  translocations.  On  a  similar 
note, in a detailed analysis of a single case of BL with 
extensive CA, there was an absence of ongoing nu-
merical CIN, supporting the notion that CA is not a 
universal surrogate marker CIN [182]. 
Chronic myeloid leukaemia 
 In CML patients, the presence of CA in CD34+ 
BCR-ABL1-positive  cells  is  an  early  event  in  CML 
development,  and  precedes  CIN  that  is  associated 
with advanced disease. Cells from chronic phase (CP) 
specimens display mostly numerical centrosome ab-
normalities with a uniform morphology, in contrast to 
those from blast crisis (BC) specimens showing irreg-
ularly-shaped  amorphous  amplification  (so-called 
"centriolar satellite material") on top of a high rate of 
numerical  alteration  [183,  184].  Cells  with  CA  are 
more evident in BC in comparison to CP specimens 
while the extent of CA strongly correlate with karyo-
type instability and aneuploidy, giving support to a 
prognostic value of centrosome status in CML [183]. 
 CML is characterized by the BCR-ABL1 trans-
location, which produces the p210BCR-ABL1 fusion pro-
tein that localizes to the centrosome in K562 cell lines. 
Cell  lines  expressing  p210BCR-ABL1  exhibit  more  CA 
than p210BCR-ABL1 negative cells [184], in keeping with 
earlier  observations  that  BCR-ABL1  transgene  ex-
pression induces CA in cell lines in a time-dependent 
manner [185]. Interestingly, tyrosine kinase inhibitors 
including imatinib, nilotinib and dasatinib lead to de 
novo induction of CA, lending a possible explanation 
to the emergence of BCR-ABL1-negative clones with 
aberrant karyotypes and secondary malignancies (e.g. 
AML and myelodysplastic syndrome) with prolonged 
treatment  using  these  drugs  [184-188].  CA  has  also 
been  detected  in  disease-unrelated  cells/tissues  in 
patients treated with tyrosine-kinase inhibitors bosu-
tinib,  dasatinib,  imatinib,  nilotinib,  sorafenib  and 
sunititib [189]. These findings though, remain more of 
a scientific enigma. It cannot be excluded that these 
genomically-unstable  cells  would  be  incapable  of 
further proliferation, and thus do not pose any sig-
nificant danger towards neoplastic development. 
Acute myeloid leukaemia 
 Numerical and structural CA has been described 
as  a  potential  cause  of  aneuploidy  in  AML.  AML 
blasts with high degree of numerical and structural 
CA  contain  numerical  CIN,  and  possess  higher  ex-
pression levels of genes coding for proteins involved 
in  stimulating  G1/S  transition,  DNA  replication,  as 
well as centrosome-associated proteins such as peri-
centrin and TUBGCP2. Furthermore, higher frequen-
cy  of  CA  is  associated  with  cytogenetically-defined 
adverse risk groups, as defined by the MRC AML 10 
trial as favourable (22.5%), intermediate (35.3%), and 
adverse  (50.3%).  Interestingly,  this  is  mainly  at-
tributed  to  structural  rather  than  numerical  centro-
some  aberrations  [190,  191].  Numerical  centrosome 
abnormalities are observed in a study of 25 patients 
with  hematopoietic  bone  marrow  failure  disorders 
with a risk for evolution into AML, including myel-
odysplastic syndrome, aplastic anaemia, and parox-
ysmal nocturnal haemoglobinuria. Increased centro-
some  copy  number  positively  correlates  with  aneu-
ploidy, and samples with  the highest percentage of 
CA tends to be aneuploid for the most chromosomes. 
This  suggests  that  CA  may  be  associated  with  the 
development  of  a  clonal  population  of  potentially 
pre-leukemic  aneuploid  hematopoietic  progenitor 
cells in bone marrow failure patients [192]. 
Adult T-cell leukaemia 
 CA is also observed in ATL, a condition causally 
linked  to  human  T  lymphotropic  virus-1  (HTLV-1) 
infection  [193,  194].  Tax,  a  HTLV-1  transactivator 
protein, localizes to the centrosome, deregulates CDK 
activity and induces CA in JPX-9 cell lines, suggesting 
an  association  with  cellular  transformation  by 
HTLV-1 and CIN in HTLV-1-infected human T cells 
[194].  Tax  may  be  directly  responsible  for  genomic 
instability and aneuploidy in ATL cells through the Int. J. Biol. Sci. 2011, 7 
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interaction  with  Ran-BP1  and  coiled-coil  protein 
TaxIBP2.  The  interaction  of  Tax  with  Ran-GTPase 
pathway via Ran-BP1 regulates centrosome stability 
and is necessary for Tax localization to centrosomes as 
well  as  its  induction  of  CA.  Disruption  of  Tax-
IBP2-Tax interaction results in failure of CA triggering 
by Tax, while TaxIBP2 downregulation leads to CA, 
suggesting that TaxIBP2 is an intrinsic block to cen-
trosome overduplication [193, 195, 196]. 
Multiple myeloma 
 CA is common in MM and is already present in 
monoclonal  gammopathy  of  undetermined  signifi-
cance  (MGUS),  suggesting  an  early  role  in  myelo-
magenesis. The percentage of plasma cells with CA 
increases progressively from MGUS to smouldering 
MM to MM, implicating that CA contributes towards 
increasing  genomic  instability  and  disease  progres-
sion [12, 197]. Structural centrosome abnormalities are 
mainly seen in MM rather than MGUS. Interestingly, 
no difference in CA exists between ploidy categories 
in  myeloma,  suggesting  that  CA  contributes  to  ge-
nomic  instability  in  both  tumour  subgroups.  Ex-
panding upon these observations, CA is also evident 
in B-cells of MM patients, supporting the existence of 
an abnormal clonal population of B-cells which may 
be precursors of malignant plasma cells [198]. 
 Chng  et  al.  demonstrated  that  a  gene  expres-
sion-derived "centrosome index" (CI) composed of the 
expression  of  genes  encoding  for  major  centrosome 
components  -  centrin,  gamma-tubulin,  and  pericen-
trin, is a strong surrogate of CA in MM. Tumours with 
high CI overexpressed genes coding for proteins in-
volved in cell cycle, proliferation, DNA damage, and 
G2/M checkpoints, as well as those associated with 
the centrosome and kinetochore or microtubules. In 
MM patients, a high CI is associated with poor prog-
nostic  features,  including  chromosome  13  deletion, 
t(4;14), t(14;16) and high plasma cell labelling index. 
Correspondingly, a high CI is a powerful independent 
poor  prognostic  factor  regardless  of  disease  phase 
(newly diagnosed or relapsed), therapeutic modality, 
or disease stage [12, 199, 200]. 
 Some  of  the  plausible  mechanisms  underlying 
CA  in  multiple  myeloma  have  been  discussed  re-
cently  [200].  Of  particular  significance,  elevated  ex-
pression  of  RHAMM  correlates  with  centrosome 
structural abnormalities in multiple myeloma; whilst 
introduction of exogenous RHAMM, which localizes 
to the centrosome, triggers an increase in centrosome 
size  as  well  as  gamma-tubulin  levels,  and  induces 
aberrant mitoses [197]. In addition, Aurora-A kinase 
has been shown to be significantly overexpressed in 
multiple  myeloma  with  a  high  centrosome  index 
[199]. 
Diagnostic, predictive and prognostic im-
plications 
 The diagnostic utility of centrosome abnormali-
ties has been repeatedly discussed in previous stud-
ies, yet its usefulness as a biomarker for cancer detec-
tion has never been thoroughly investigated. Based on 
earlier observations, CA in normal or benign tissue is 
a rare phenomenon. In most studies, no CA could be 
detected in normal human cells including those of the 
breast, prostate, lung, brain, colon [10], bladder [76], 
kidney [81], cervix [84], testis [104], ovary [105], liver 
[117], pancreas [122], head and neck [157], and blood 
[183]  in  contrast  to  their  malignant  counterparts. 
However, in studies on benign breast lesions, centro-
some abnormalities were not found in mastopathia or 
fibroadenoma  [29],  while  another  study  observed 
structural  centrosomal  abnormalities  occasionally  in 
the benign lesions studied (3 of 25, including masto-
pathia,  intraductal  papilloma  and  fibrocystic  mas-
topathy)  [35].  Apart  from  those  of  the  breast, 
non-malignant tumours from other sites such as soft 
tissue  [81,  165,  166]  and  pancreatic  adenoma  [122] 
have been shown to harbour CA, suggesting that the 
presence of CA alone is not a sufficient criterion to 
diagnose  malignancy.  In  addition,  although  CA  is 
frequently present to some extent in most cancers, it is 
not  an  invariable  phenomenon  [Table  1].  Thus,  the 
lack of CA may not necessarily exclude malignancy 
either. Nonetheless, the utility of centrosome status as 
a  differential  diagnostic  marker  may  be  augmented 
when employed in adjunct to contemporary methods. 
CA may also be of clinical utility where tissue availa-
bility is limited, as demonstrated in cytological aspi-
rates of breast lesions [29, 35]. 
 In  HNSCC,  those  with  high  degree  of  CA  in 
tumour  margins  recur  more  frequently  than  those 
with less CA. This finding is interesting, given that 
these  margins  are  histologically  negative  for  malig-
nant cells, the latter of which clinically implies ade-
quate  surgical  resection  [154].  Given  such  observa-
tions, it is tempting to speculate that malignant, or at 
least  potentially  malignant  cells  harbouring  CA 
within these margins that escape histological detec-
tion, may be responsible for eventual tumour recur-
rence and poor prognosis. In parallel, CA occurs in 
matched adjacent normal or hyperplastic regions of 
NSCLC as well [128, 129], although their clinical sig-
nificance remains unknown. In such cases, CA in the 
tumours and/or their margins may define a subgroup 
of patients who may benefit from more extensive cu-Int. J. Biol. Sci. 2011, 7 
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rative surgery,  more aggressive adjuvant treatment, 
and closer monitoring for disease recurrence. 
 Finally,  can  CA  be  a  surrogate  for  aggressive 
tumour phenotype? Phenotypic heterogeneity gener-
ated as a result of CIN and aneuploidy allows for se-
lection of a superior karyotypic clone that may confer 
survival  advantage  through  a  Darwinian  selection 
process, which in turn promotes tumour aggressive-
ness,  progression,  metastasis,  and  chemoresistance 
[Figure 1]. As summarized in Table 3, CA is not only 
characteristic of tumours in general, but is also more 
pronounced in advanced stage and tumour grade, as 
well as correlates with early disease recurrence, dis-
ease  progression  and  poor  survival  in  many  cases. 
Together  with  other  established  prognostic  factors, 
CA may prove to be helpful in predicting outcomes 
and survival of patients with cancer. 
The centrosome as a cancer therapeutic 
target 
Potentially, the centrosome can be a therapeutic 
target for the treatment of cancers. The selective kill-
ing of cells with CA has been investigated via target-
ing  specific  altered  proteins/pathways  peculiar  to 
these  cells.  Centrosome  duplication  in  normal 
non-neoplastic  cells  differs  mechanistically  from 
pathways  leading  to  CA  in  cancer  cells,  and  these 
differences may be exploited to selectively kill target 
cancer cells while leaving normal cells relatively un-
affected  [89-91].  Of  particular  significance,  small 
molecule centrosome-associated protein kinase inhib-
itors, such as Aurora-A kinase and Polo-like kinase 
inhibitors have recently shown promising results in 
clinical trials [201]. Also, AhR agonists such as indi-
rubins reduce centriole overduplication and may im-
ply a novel role for chemoprevention in breast cancer 
[65].  Likewise,  targeting  the  compensatory  mecha-
nisms of bipolar spindle formation, such as inhibition 
of centrosome clustering, may be a potential mode of 
promoting cancer cell death [21]. Conversely, it may 
also be plausible that agents that promote centrosome 
clustering may delay tumour progression by limiting 
CIN. 
Another  attractive  approach  to  discriminatory 
cancer cell eradication invokes exploiting the possible 
additional burden of excess centrosomes on the cell 
cycle [202]. In these cells with CA, the threshold to 
apoptosis induced by drugs [203] or radiation [145] 
may be much lower. For example, the partial inhibi-
tion  of  PARP1  in  BRCA1-deficient  cells  has  been 
suggested to represent a possible chemopreventive or 
therapeutic  approach  for  BRCA1-deficient  breast 
cancers, via its induction of severe chromosome ab-
errations,  CA,  telomere  dysfunction  and  apoptosis 
[204]. Survivin inhibition in glioma cells has also been 
shown  to  enhance  CIN  and  radiosensitivity  via  in-
duction of CA [145]. The induction of CA using agents 
that delay S-phase but at insufficient doses to trigger 
apoptosis, such as low dose 5-FU, has been suggested 
as a novel mode of chemosensitization approach to 
cancer therapy [203]. However in all these approach-
es, one should be mindful of evoking CA in normal 
cells and risk of secondary carcinogenesis as a con-
sequence  of  amplified  genomic  instability.  In  addi-
tion, cancer cells which evade apoptosis despite being 
induced with a greater degree of centrosome aberra-
tion and genomic instability may eventually develop 
an even more aggressive phenotype. These theoretical 
concerns  warrant  further  investigations  before  this 
therapeutic approach may be considered for clinical 
utility. 
Conclusion and future perspectives 
 CA is a common phenomenon in various human 
malignancies  and  may  play  a  dominant  role  in  tu-
mour  initiation  and  progression.  Given  the  present 
evidence, it is most likely that CA represents, but not 
necessarily always, one of the major mechanisms un-
derlying  CIN  and  aneuploidy  in  cancer  cells.  Alt-
hough the list of clinical studies on centrosomes and 
human  cancers  is  growing  rapidly,  methodological 
issues place upon a significant limitation on data in-
terpretation,  as  many  studies  use  only  su-
per-numeration as the sole marker for CA rather than 
considering  structural  and  functional  aberrations 
concurrently.  Although  these  types  of  aberrations 
often occur together, their biological and clinical con-
sequences may be different. In addition, studies based 
on single section histological specimens will discount 
centrosomes unseen at that particular cut, therefore 
underestimating the true incidence of CA, as well as 
their  association  with  concurrent  molecular  events. 
Future studies should take on a holistic approach to 
understanding  the  contribution  of  numerical,  struc-
tural as well as functional centrosome abnormalities 
to specific human cancers throughout the course of 
tumour development,  with particular respect to the 
generation  of  CIN  and  aneuploidy.  Finally,  a 
cell-to-cell  based  examination  for  specific  molecular 
alterations  associated  with  centrosome  defects  may 
reveal  unique  mechanistic  correlations  that  would 
have been missed on simple linear correlative analy-
sis.  A  better  delineation  of  the  detailed  molecular 
circuitry  regulating  centrosome  biology  will  be  in-
dispensable for a more intricate manipulation of these 
pathways for clinical application. Int. J. Biol. Sci. 2011, 7 
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Review criteria 
Information  for  this  Review  was  compiled  by 
searching the PubMed database for articles published 
until  June  2011.  Only  articles  published  in  English 
were considered. Search terms included “centrosome” 
and "cancer", in association with the terms "breast", 
"prostate", "bladder", kidney", "cervix", "ovary", “gas-
tric”,  “colorectal”,  hepatobiliary”,  “prostate”,  “blad-
der”,  “lung”,  ”ovary”,  “testicular”,  "colorectal", 
"hepatobiliary", "pancreas", "lung", “cerebral”, "head 
and  neck",  "sarcoma",  "lymphoma",  "leukaemia", 
"myeloma",  "carcinogenesis",  “prognosis”,  “progres-
sion”, “survival”, “biomarker”, and “chemotherapy”. 
Full articles were retrieved, and further information 
was obtained from relevant references. The focus was 
on relevant primary literature rather than review pa-
pers to compile this Review. A specific emphasis was 
placed on literature focusing on the frequency of CA, 
as well as its clinical relevance in solid and haemato-
logical cancers in human. Relevant papers on cell line 
or animal models were also discussed if deemed re-
lated to current evidence from clinical studies. 
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